Thursday, December 1, 2016

HALAVEN® for the treatment of metastatic breast cancer

 300x250

 HALAVEN® for the treatment of metastatic breast cancer

Although some women lived longer and some women did not live as long, women with metastatic breast cancer (mBC) who were treated with HALAVEN in a clinical trial lived an average of 13.2 months compared with women treated with other chemotherapy or hormone therapy, who lived an average of 10.6 months.

No comments:

Post a Comment